Roivant Sciences (NASDAQ:ROIV) reported quarterly losses of $(0.39) per share which missed the analyst consensus estimate of $(0.32) by 21.88 percent.
Morgan Stanley Downgrades Neurocrine Biosciences to Equal-Weight, Announces $112 Price Target
Morgan Stanley analyst Jeffrey Hung downgrades Neurocrine Biosciences (NASDAQ:NBIX) from Overweight to Equal-Weight and announces $112 price target.